UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
Position in GRFS — Grifols SA
CIK 861177
NEW YORK, NY
Position in GRFS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$6,655
-$883 QoQ
Shares Held
940
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#131
of 164 holders
Holding Since
Mar 2020
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $25,598,342,767 across 16 Drug Manufacturers - General names. GRFS ranks #16 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
7,209,385 | $8,647,153,365 | |
| 2 | JNJ |
Johnson & Johnson
|
18,416,123 | $4,677,142,752 | |
| 3 | ABBV |
AbbVie Inc.
|
14,267,697 | $3,590,323,267 | |
| 4 | MRK |
Merck & Co., Inc.
|
19,547,171 | $2,511,811,470 | |
| 5 | AMGN |
Amgen Inc
|
5,390,910 | $1,952,156,323 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
12,986,591 | $1,640,725,902 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
22,839,010 | $1,315,983,749 | |
| 8 | PFE |
Pfizer Inc
|
36,157,306 | $870,667,923 |
All Filings in GRFS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,655 | 940 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $7,538 | 940 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $2,720 | 291 | Shares | Defined | 2026-02-13 | |
| 2023-06-30 | $3,435 | 375 | Shares | Defined | 2023-08-11 | |
| 2023-03-31 | $2,763 | 375 | Shares | Defined | 2023-05-15 | |
| 2020-06-30 | $8,609,444 | 472,009 | Shares | Sole | 2020-08-14 | |
| 2020-03-31 | $44,957,132 | 2,232,231 | Shares | Defined | 2020-05-15 | |
| No filing history on record for this holder in this stock. | ||||||